CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif, Feb. 07, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. CDNA, a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will be participating in four upcoming investor conferences.

Leerink Partners 7^th Annual Global Healthcare Conference in New York City

• Peter Maag will host investor meetings on Thursday, February 15^th

BTIG Healthcare Conference in Snowbird, Utah

• Peter Maag will host investor meetings on Wednesday and Thursday, February 28^th and March 1^st

30^th Annual Roth Conference in Laguna Niguel, California

• Peter Maag and Michael Bell will host investor meetings on Monday and Tuesday, March 12^th and 13^th

H. C. Wainwright Global Life Sciences Conference in Monte Carlo, Monaco

• Peter Maag will present on Monday, April 9^th, and host investor meetings on Monday and Tuesday, April 9^th and 10^th

A live audio webcast of the H. C. Wainwright Global Life Sciences Conference will be available online from the investor relations section of the CareDx website at http://investors.caredx.com. The webcast replay of the presentation will be available approximately one hour following the conclusion of the live presentation and will be available on the Company's website for 90 days. Management will be hosting one-on-one meetings for the Leerink Partners 7^th Annual Global Healthcare Conference, the BTIG Healthcare Conference and the 30^th Annual Roth Conference and no webcasts will be available for these events.

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: www.CareDx.com.

CONTACTS:

CareDx, Inc.

Sasha King

Chief Commercial Officer

415-287-2393

sking@caredx.com

Investor Relations

David Clair

Integrated Corporate Relations, Inc.

646-277-1266

david.clair@icrinc.com